Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 55Gynecologic 14Thoracic 12Genitourinary 8Breast 8CNS 7Head & Neck 6Sarcoma 4Endocrine 4Dermatologic 3NET 2Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 187Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Hematologic Neoplasms 98Leukemia, Lymphocytic, Chronic, B-Cell 88Myelodysplastic Syndromes 72Leukemia 63Lymphoma 45Multiple Myeloma 40Lymphoma, Non-Hodgkin 36Leukemia, Myelogenous, Chronic, BCR-ABL Positive 35Burkitt Lymphoma 28Neoplasms 25Recurrence 23Leukemia, Myelomonocytic, Chronic 23Myeloproliferative Disorders 21Lymphoma, Large B-Cell, Diffuse 20Hodgkin Disease 20Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 19Leukemia, Biphenotypic, Acute 18Lymphoma, Mantle-Cell 17Leukemia, B-Cell 17Lymphoma, B-Cell 15Lymphoma, Follicular 14Waldenstrom Macroglobulinemia 13Anemia, Refractory, with Excess of Blasts 13Myelodysplastic-Myeloproliferative Diseases 11Lymphoma, B-Cell, Marginal Zone 11Leukemia, Hairy Cell 9Blast Crisis 9Primary Myelofibrosis 8

Interventions

olutasidenib 1Cytochrome P-450 CYP3A 1Cytochrome P-450 CYP2C9 1Cytochrome P-450 CYP2C8 1Cytochrome P-450 CYP2C19 1Cytochrome P-450 CYP2B6 1Cytochrome P-450 CYP1A2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × Other hematologic neoplasm × 30 days × Clear all
NCT07486713 2026-06-05

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡